Skip to main content
Top
Published in: Cancer and Metastasis Reviews 1/2023

21-01-2023

Insights into the role of senescence in tumor dormancy: mechanisms and applications

Authors: Valerie J. DeLuca, Tareq Saleh

Published in: Cancer and Metastasis Reviews | Issue 1/2023

Login to get access

Abstract

One of the most formidable challenges in oncology and tumor biology research is to provide an accurate understanding of tumor dormancy mechanisms. Dormancy refers to the ability of tumor cells to go undetected in the body for a prolonged period, followed by “spontaneous” escape. Various models of dormancy have been postulated, including angiogenic, immune-mediated, and cellular dormancy. While the former two propose mechanisms by which tumor growth may remain static at a population level, cellular dormancy refers to molecular processes that restrict proliferation at the cell level. Senescence is a form of growth arrest, during which cells undergo distinct phenotypic, epigenetic, and metabolic changes. Senescence is also associated with the development of a robust secretome, comprised of various chemokines and cytokines that interact with the surrounding microenvironment, including other tumor cells, stromal cells, endothelial cells, and immune cells. Both tumor and non-tumor cells can undergo senescence following various stressors, many of which are present during tumorigenesis and therapy. As such, senescent cells are present within forming tumors and in residual tumors post-treatment and therefore play a major role in tumor biology. However, the contributions of senescence to dormancy are largely understudied. Here, we provide an overview of multiple processes that have been well established as being involved in tumor dormancy, and we speculate on how senescence may contribute to these mechanisms.
Literature
27.
35.
go back to reference Malaquin, N., Vancayseele, A., Gilbert, S., Antenor-Habazac, L., Olivier, M. A., Ait Ali Brahem, Z., Rodier, F. (2020). DNA damage- but not enzalutamide-induced senescence in prostate cancer promotes senolytic Bcl-xL inhibitor sensitivity. Cells, 9(7). https://doi.org/10.3390/cells9071593 Malaquin, N., Vancayseele, A., Gilbert, S., Antenor-Habazac, L., Olivier, M. A., Ait Ali Brahem, Z., Rodier, F. (2020). DNA damage- but not enzalutamide-induced senescence in prostate cancer promotes senolytic Bcl-xL inhibitor sensitivity. Cells, 9(7). https://​doi.​org/​10.​3390/​cells9071593
41.
go back to reference Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J., Joel, S. P., te Poele, R. H., & Joel, S. P. (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Research, 62(6), 1876–1883. Poele, R. H., Okorokov, A. L., Jardine, L., Cummings, J., Joel, S. P., te Poele, R. H., & Joel, S. P. (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Research, 62(6), 1876–1883.
65.
go back to reference Beausejour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003). Reversal of human cellular senescence: Roles of the p53 and p16 pathways. The European Molecular Biology Organization Journal, 22(16), 4212–4222.CrossRef Beausejour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003). Reversal of human cellular senescence: Roles of the p53 and p16 pathways. The European Molecular Biology Organization Journal, 22(16), 4212–4222.CrossRef
77.
go back to reference Was, H., Barszcz, K., Czarnecka, J., Kowalczyk, A., Uzarowska, E., Koza, P., & Sikora, E. (2017). Bafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD / SCID mice. Oncotarget, 8(6), 9303–9322.CrossRefPubMed Was, H., Barszcz, K., Czarnecka, J., Kowalczyk, A., Uzarowska, E., Koza, P., & Sikora, E. (2017). Bafilomycin A1 triggers proliferative potential of senescent cancer cells in vitro and in NOD / SCID mice. Oncotarget, 8(6), 9303–9322.CrossRefPubMed
81.
go back to reference Zhang, N., Ji, J., Zhou, D., Liu, X., Zhang, X., Liu, Y., & Zhang, Y. (2021). The interaction of the senescent and adjacent breast cancer cells promotes the metastasis of heterogeneous breast cancer cells through Notch signaling. International Journal of Molecular Sciences, 22(2), 1–13. https://doi.org/10.3390/IJMS22020849CrossRef Zhang, N., Ji, J., Zhou, D., Liu, X., Zhang, X., Liu, Y., & Zhang, Y. (2021). The interaction of the senescent and adjacent breast cancer cells promotes the metastasis of heterogeneous breast cancer cells through Notch signaling. International Journal of Molecular Sciences, 22(2), 1–13. https://​doi.​org/​10.​3390/​IJMS22020849CrossRef
85.
go back to reference Wang, S., Huang, S., Zhao, X., Zhang, Q., Wu, M., Sun, F., & Wu, D. (2014). Enrichment of prostate cancer stem cells from primary prostate cancer cultures of biopsy samples. International Journal of Clinical and Experimental Pathology, 7(1), 184.PubMed Wang, S., Huang, S., Zhao, X., Zhang, Q., Wu, M., Sun, F., & Wu, D. (2014). Enrichment of prostate cancer stem cells from primary prostate cancer cultures of biopsy samples. International Journal of Clinical and Experimental Pathology, 7(1), 184.PubMed
87.
go back to reference Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., & Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821–5828.PubMed Singh, S. K., Clarke, I. D., Terasaki, M., Bonn, V. E., Hawkins, C., Squire, J., & Dirks, P. B. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Research, 63(18), 5821–5828.PubMed
90.
go back to reference Bertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., & Sozzi, G. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences, 106(38), 16281–16286. https://doi.org/10.1073/PNAS.0905653106CrossRef Bertolini, G., Roz, L., Perego, P., Tortoreto, M., Fontanella, E., Gatti, L., & Sozzi, G. (2009). Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proceedings of the National Academy of Sciences, 106(38), 16281–16286. https://​doi.​org/​10.​1073/​PNAS.​0905653106CrossRef
118.
go back to reference Rosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., & Amaravadi, R. K. (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy, 10(8), 1359–68.CrossRefPubMedPubMedCentral Rosenfeld, M. R., Ye, X., Supko, J. G., Desideri, S., Grossman, S. A., Brem, S., & Amaravadi, R. K. (2014). A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy, 10(8), 1359–68.CrossRefPubMedPubMedCentral
120.
go back to reference Neal, J. W., Wakelee, H. A., Feliciano, J. L., Goldberg, S. B., Morgensztern, D., Das, M. S., … Sequist, L. V. (2014). A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 8088–8088. https://doi.org/10.1200/jco.2014.32.15_suppl.8088 Neal, J. W., Wakelee, H. A., Feliciano, J. L., Goldberg, S. B., Morgensztern, D., Das, M. S., … Sequist, L. V. (2014). A multicenter randomized phase II trial of erlotinib with and without hydroxychloroquine (HCQ) in TKI-naive patients (pts) with epidermal growth factor receptor (EGFR) mutant advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology, 8088–8088. https://​doi.​org/​10.​1200/​jco.​2014.​32.​15_​suppl.​8088
128.
go back to reference La Belle Flynn, A., Calhoun, B. C., Sharma, A., Chang, J. C., Almasan, A., & Schiemann, W. P. (2019). Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nature communications, 10(1). https://doi.org/10.1038/S41467-019-11640-9 La Belle Flynn, A., Calhoun, B. C., Sharma, A., Chang, J. C., Almasan, A., & Schiemann, W. P. (2019). Autophagy inhibition elicits emergence from metastatic dormancy by inducing and stabilizing Pfkfb3 expression. Nature communications, 10(1). https://​doi.​org/​10.​1038/​S41467-019-11640-9
132.
go back to reference Milczarek, M., Wiktorska, K., Mielczarek, L., Koronkiewicz, M., Dąbrowska, A., Lubelska, K., & Chilmonczyk, Z. (2018). Autophagic cell death and premature senescence: New mechanism of 5-fluorouracil and sulforaphane synergistic anticancer effect in MDA-MB-231 triple negative breast cancer cell line. Food and Chemical Toxicology, 111, 1–8. https://doi.org/10.1016/j.fct.2017.10.056CrossRefPubMed Milczarek, M., Wiktorska, K., Mielczarek, L., Koronkiewicz, M., Dąbrowska, A., Lubelska, K., & Chilmonczyk, Z. (2018). Autophagic cell death and premature senescence: New mechanism of 5-fluorouracil and sulforaphane synergistic anticancer effect in MDA-MB-231 triple negative breast cancer cell line. Food and Chemical Toxicology, 111, 1–8. https://​doi.​org/​10.​1016/​j.​fct.​2017.​10.​056CrossRefPubMed
137.
go back to reference Bojko, A., Staniak, K., Czarnecka-herok, J., & Sunderland, P. (n.d.). Improved autophagic flux in escapers from doxorubicin-induced senescence / polyploidy of breast cancer cells, 1–22. Bojko, A., Staniak, K., Czarnecka-herok, J., & Sunderland, P. (n.d.). Improved autophagic flux in escapers from doxorubicin-induced senescence / polyploidy of breast cancer cells, 1–22.
144.
go back to reference Mannan, R., Wang, X., Bawa, P. S., Spratt, D. E., Wilson, A., Jentzen, J., … Mehra, R. (2020). Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: Observations from the Michigan Legacy Tissue Program. Medical Oncology, 37(3). https://doi.org/10.1007/s12032-020-1341-6 Mannan, R., Wang, X., Bawa, P. S., Spratt, D. E., Wilson, A., Jentzen, J., … Mehra, R. (2020). Polypoidal giant cancer cells in metastatic castration-resistant prostate cancer: Observations from the Michigan Legacy Tissue Program. Medical Oncology, 37(3). https://​doi.​org/​10.​1007/​s12032-020-1341-6
149.
go back to reference Pustovalova, M., Blokhina, T., Alhaddad, L., Chigasova, A., Chuprov-Netochin, R., Veviorskiy, A., & Leonov, S. (2022). CD44+ and CD133+ non-small cell lung cancer cells exhibit DNA damage response pathways and dormant polyploid giant cancer cell enrichment relating to their p53 status. International Journal of Molecular Sciences, 23(9), 4922. https://doi.org/10.3390/IJMS23094922CrossRefPubMedPubMedCentral Pustovalova, M., Blokhina, T., Alhaddad, L., Chigasova, A., Chuprov-Netochin, R., Veviorskiy, A., & Leonov, S. (2022). CD44+ and CD133+ non-small cell lung cancer cells exhibit DNA damage response pathways and dormant polyploid giant cancer cell enrichment relating to their p53 status. International Journal of Molecular Sciences, 23(9), 4922. https://​doi.​org/​10.​3390/​IJMS23094922CrossRefPubMedPubMedCentral
151.
go back to reference Fei, F., Zhang, M., Li, B., Zhao, L., Wang, H., Liu, L., … Zhang, S. (2019). Formation of polyploid giant cancer cells involves in the prognostic value of neoadjuvant chemoradiation in locally advanced rectal cancer. Journal of Oncology, 2019. https://doi.org/10.1155/2019/2316436 Fei, F., Zhang, M., Li, B., Zhao, L., Wang, H., Liu, L., … Zhang, S. (2019). Formation of polyploid giant cancer cells involves in the prognostic value of neoadjuvant chemoradiation in locally advanced rectal cancer. Journal of Oncology, 2019. https://​doi.​org/​10.​1155/​2019/​2316436
152.
163.
go back to reference Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D., & Johnson, R. S. (1999). Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Resear, 59(7), 1592–1598. Grunstein, J., Roberts, W. G., Mathieu-Costello, O., Hanahan, D., & Johnson, R. S. (1999). Tumor-derived expression of vascular endothelial growth factor is a critical factor in tumor expansion and vascular function. Cancer Resear, 59(7), 1592–1598.
165.
go back to reference Guarino, B., Katari, V., Adapala, R., Bhavnani, N., Dougherty, J., Khan, M., & Thodeti, C. (2021). Tumor-derived extracellular vesicles induce abnormal angiogenesis via TRPV4 downregulation and subsequent activation of YAP and VEGFR2. Frontiers in Boengineering and Biotechnology, 9, 790489. https://doi.org/10.3389/FBIOE.2021.790489CrossRef Guarino, B., Katari, V., Adapala, R., Bhavnani, N., Dougherty, J., Khan, M., & Thodeti, C. (2021). Tumor-derived extracellular vesicles induce abnormal angiogenesis via TRPV4 downregulation and subsequent activation of YAP and VEGFR2. Frontiers in Boengineering and Biotechnology, 9, 790489. https://​doi.​org/​10.​3389/​FBIOE.​2021.​790489CrossRef
169.
go back to reference Huss, W. J., Hanrahan, C. F., Barrios, R. J., Simons, J. W., & Greenberg, N. M. (2001). Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Research, 61(6), 2736–2743.PubMed Huss, W. J., Hanrahan, C. F., Barrios, R. J., Simons, J. W., & Greenberg, N. M. (2001). Angiogenesis and prostate cancer: Identification of a molecular progression switch. Cancer Research, 61(6), 2736–2743.PubMed
170.
go back to reference Guba, M., Cernaianu, G., Koehl, G., Geissler, E. K., Jauch, K. W., Anthuber, M., & Steinbauer, M. (2001). A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Research, 61(14), 5575–9.PubMed Guba, M., Cernaianu, G., Koehl, G., Geissler, E. K., Jauch, K. W., Anthuber, M., & Steinbauer, M. (2001). A primary tumor promotes dormancy of solitary tumor cells before inhibiting angiogenesis. Cancer Research, 61(14), 5575–9.PubMed
175.
go back to reference Mikuła-Pietrasik, J., Sosińska, P., Naumowicz, E., Maksin, K., Piotrowska, H., Woźniak, A., & Książek, K. (2016). Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo. Clinical and Experimental Metastasis, 33(1), 15–27. https://doi.org/10.1007/S10585-015-9753-YCrossRefPubMed Mikuła-Pietrasik, J., Sosińska, P., Naumowicz, E., Maksin, K., Piotrowska, H., Woźniak, A., & Książek, K. (2016). Senescent peritoneal mesothelium induces a pro-angiogenic phenotype in ovarian cancer cells in vitro and in a mouse xenograft model in vivo. Clinical and Experimental Metastasis, 33(1), 15–27. https://​doi.​org/​10.​1007/​S10585-015-9753-YCrossRefPubMed
Metadata
Title
Insights into the role of senescence in tumor dormancy: mechanisms and applications
Authors
Valerie J. DeLuca
Tareq Saleh
Publication date
21-01-2023
Publisher
Springer US
Published in
Cancer and Metastasis Reviews / Issue 1/2023
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI
https://doi.org/10.1007/s10555-023-10082-6

Other articles of this Issue 1/2023

Cancer and Metastasis Reviews 1/2023 Go to the issue
Live Webinar | 01-10-2024 | 12:30 (CEST)

Recent advances in the use of CAR T-cell therapies in relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma

Live: Tuesday 1st October 2024, 12:30-14:00 (CEST)

In this live webinar, Professor Martin Dreyling and an esteemed, international panel of CAR-T experts will discuss the very latest data on the safety, efficacy and clinical impact of CAR T-cell therapies in the treatment of r/r DLBCL and r/r FL, as presented at ASH 2023, EU CAR-T 2024, and EHA 2024. 

Please note, this webinar is not intended for healthcare professionals based in the US and UK.

Sponsored by: Novartis Pharma AG

Chaired by: Prof. Martin Dreyling
Developed by: Springer Healthcare